Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019

April 16, 2019 — CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic...

Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019

March 19, 2019 — The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial...

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019

The American College of Cardiology (ACC) released a list of the...

Apple Heart Study Demonstrates Ability of Wearable Technology to Detect Atrial Fibrillation
News | Wearables | March 18, 2019

March 18, 2019 — Researchers from the Stanford University School of Medicine presented preliminary results of the...

First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019

February 4, 2019 – Biosense Webster has enrolled and treated the first patient in its U.S....

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019

January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral...

Acutus AcQMap Imaging System Helps Eliminate Arrhythmia With Single Ablation
News | EP Mapping and Imaging Systems | January 28, 2019

January 28, 2019 — Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the...

FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019

January 21, 2019 — Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force...

Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018

December 18, 2018 — Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the...

First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018

November 30, 2018 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has...

Russel Pate, Ph.D., Univerity Of South Carolina, chair of the National Physical Activity Plan Alliance. #AHA18

The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines for Americans at the American Heart Association’s (AHA) 2018 Scientific Sessions this week. Chicago. It provides evidence-based recommendations for youth ages three through 17 and adults to safely get the physical activity and was a major topic of discussion. Pictured here is Russel Pate, Ph.D., Univerity Of South Carolina, chair of the National Physical Activity Plan Alliance, presenting on the main stage at AHA, with details relat d to the new guidelines.

Feature | AHA | November 20, 2018

November 7, 2018 — Here is a list of some of the key clinical trial presentations at the 2018...

FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018

October 9, 2018 — Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA)...

Overlay Init